Pharmacodynamics of Pre-Operative PD1 Checkpoint Blockade and Receptor Activator of NFkB Ligand (RANKL) Inhibition in Non-Small Cell Lung Cancer (NSCLC): study protocol for a multicentre open-label phase 1B/2 translational trial (POPCORN)

CURRENT STATUS: ACCEPTED

Elizabeth Stephanie Ahern
Department of Medical Oncology, Royal Brisbane and Womens Hospital
elizabeth.ahern2@health.qld.gov.au
Corresponding Author
ORCiD: https://orcid.org/0000-0002-2062-5695

Annette Cubitt
Royal Brisbane and Women's Hospital

Emma Ballard
QIMR Berghofer Medical Research Institute

Michele W. L. Teng
QIMR Berghofer Medical Research Institute

William C. Dougall
QIMR Berghofer Medical Research Institute

Mark J. Smyth
QIMR Berghofer Medical Research Institute

David Godbolt
The Prince Charles Hospital

Rishendran Naidoo
The Prince Charles Hospital

Amanda Goldrick
Amgen. Inc

Brett G. M. Hughes
Royal Brisbane and Womens Hospital
Abstract

Background

Neoadjuvant immunotherapy targeting the immune checkpoint programmed death-1 (PD-1) is under investigation in various tumour settings including non-small-cell lung cancer (NSCLC). Preclinical models demonstrate the superior power of immunotherapy given in the neoadjuvant (pre-operative) compared with adjuvant (post-operative) setting to eradicate metastatic disease and induce long-lasting antigen-specific immunity. Novel effective immunotherapy combinations are widely sought in the oncology field, targeting non-redundant mechanisms of immune evasion. A promising combination partner with anti-PD1 in NSCLC is denosumab, a monoclonal antibody blocking Receptor Activator of NF-κB Ligand (RANKL). In preclinical cancer models, and a large retrospective case series in NSCLC, anti-cancer activity of combination immune checkpoint inhibition (ICI) and denosumab has been reported. Furthermore, clinical trials of ICI and denosumab are underway in advanced melanoma and clear-cell renal cell carcinoma. However, the mechanism of action of combination anti-PD1 and anti-RANKL is poorly defined.

Methods

This open-label multicentre trial will randomise by minimisation 30 patients with resectable stage IA (primary > 2cm) to IIIA NSCLC to a neoadjuvant treatment regime of either two doses of nivolumab (3 mg/kg every 2 weeks) or two doses of nivolumab (same regimen) plus denosumab (120 mg every 2 weeks, following nivolumab). Each treatment arm is of equal size, and be approximately balanced with respect to histology (squamous vs. non-squamous) and clinical stage (I-II vs IIIA). All patients will receive surgery for their tumour two weeks after the final dose of neoadjuvant therapy. The primary outcome will be translational research to define the tumour-immune correlates of combination therapy compared with monotherapy. Key secondary outcomes will include a comparison of rates of the following between each arm: toxicity, response (pathological and radiological), and microscopically complete resection.

Discussion

The POPCORN study provides a unique platform for translational research to determine the
mechanism of action of a novel proposed combination immunotherapy for cancer.

Trial registration

Prospectively registered on Australian New Zealand Clinical Trials Registry (ACTRN12618001121257) on 06/07/2018.

Background

In early-stage and selected locally-advanced non-small cell lung cancer (NSCLC), surgical excision is recommended where possible (stage I, II and selected IIIA). Surgery improves cure in stage 1-2 disease (1). Unfortunately, evidence suggests that less than 30% NSCLC patients receive surgery due to factors such as tumour stage (i.e. locally-advanced unresectable or metastatic disease at presentation) or physiologic unsuitability for the required surgery (2-4). Furthermore, survival after surgical excision of early-stage NSCLC remains suboptimal, and is stage-dependent (5). Adjuvant chemotherapy is offered to selected patients and when indicated improves absolute survival rates by approximately 5% (6, 7). In chemotherapy trials, neoadjuvant approaches have broadly equivalent efficacy but a higher rate of completion of all planned cycles (8, 9). Major pathological response (MPR), indicating \( \leq 10\% \) viable tumour remaining at the time of surgery, is significantly correlated with improved survival after the administration of neoadjuvant chemotherapy in NSCLC (10).

More recently, immunotherapy blocking immune checkpoints expressed by T-lymphocytes (immune checkpoint inhibition, ICI) demonstrated superior outcomes compared with chemotherapy in various settings in advanced NSCLC (11-15). Such treatment aims to reverse tumour-mediated immune suppression which leads to dysfunctional tumour-associated immune cells. Furthermore, in mouse cancer models, neoadjuvant immunotherapy demonstrated superior power to eradicate micro-metastatic disease and improve survival when compared with adjuvant immunotherapy (16). The mechanism involves induction of long-lasting antigen-specific T-cell memory (16). In 2018, a small phase II trial showed that two doses of neoadjuvant nivolumab (antibody blocking programmed death-1, PD1) in patients with resectable NSCLC resulted in an impressive rate of pathological response (45% major pathological response) and was well-tolerated (17). This rate of major pathological
response is higher than that reported historically for neoadjuvant chemotherapy in similar patient
groups (22%) (10), albeit with a small patient cohort. In that trial, effective neoadjuvant
immunotherapy was associated with higher clonality of tumour-infiltrating T-lymphocytes and an
induction and expansion of tumour antigen-specific T-lymphocytes detected in peripheral blood (17).
Pathologically, tumour regression was accompanied by marked signs of local immune activity
including the influx of lymphocytes and macrophages, and the creation of tertiary lymphoid
structures, along with tumour-cell death (18). Subsequently, preliminary outcomes of further early
phase trials of neoadjuvant nivolumab or atezolizumab (antibody blocking PD1-Ligand 1, PD-L1) with
or without chemotherapy have been reported, with these therapies proving well-tolerated and with
considerable evidence of clinical efficacy (19-21).

Receptor Activator of NF-kB (RANKL) (TNFSF11A) is a member of the tumor necrosis factor
superfamily. Denosumab (Amgen, Inc.) is a fully-human IgG2 monoclonal antibody blocking RANKL
and is FDA-approved in various malignant and non-malignant indications including bone metastases
and osteoporosis given its anti-osteoclastic activity (22). The receptor for RANKL, RANK (TNFSFR11), is
expressed by osteoclasts and other cells of the monocyte-macrophage lineage, while RANKL is
expressed by activated T cells (23). In several preclinical cancer models, blockade of RANKL improved
the efficacy of various ICI, including anti-PD1; of note, RANKL blockade alone had minimal single
agent efficacy (24-26). Some exceptional anti-tumour responses have been reported in case reports
following concurrent ICI and denosumab administration in patients with advanced melanoma, and
small clinical retrospective series have reported encouraging response rates with similar denosumab-
ICI combinations in advanced melanoma (27). Two phase II trials are underway assessing efficacy of
denosumab with various ICI in advanced melanoma (NCT03280667) and advanced clear cell renal cell
carcinoma (NCT03161756). However, these trials do not include an ICI-alone comparator arm, which
will complicate interpretation with respect to magnitude and mechanism of effect of blocking RANKL
in addition to ICI in cancer.
The totality of evidence suggests that NSCLC is a good tumour type in which to explore this unanswered mechanistic question. RANK can be expressed by human lung cancer cells, and higher RANKL gene expression is significantly correlated with poorer survival in published human NSCLC datasets drawing from large mRNA expression data sets (28). Some clinical evidence suggests that blocking RANKL with denosumab may improve survival in patients with advanced NSCLC, independent of effects on bone metastases. Post-hoc survival analysis of a large subset of patients with NSCLC (n=702) in a larger randomised phase III trial which compared denosumab with zoledronic acid (an alternative anti-resorptive agent active in skeletal metastases) revealed a significant benefit of denosumab (HR for survival 0.80, 95% CI 0.67 – 0.95, p = 0.01) (29, 30). In a relatively large retrospective case series of patients with advanced NSCLC, duration of concurrent denosumab therapy with ICI was associated with significantly improved survival in advanced NSCLC (27).

Taken together, evidence suggests that neoadjuvant immunotherapy comprises a promising approach in NSCLC, and that anti-RANKL may prove a rational combination partner with ICI in this indication. Furthermore, the conduct of neoadjuvant trials is particularly favourable for translational research, as baseline biopsies followed by systemic therapy and then surgery allows easy access to pre- and post-treatment tissue and blood samples for correlative testing. The mechanism of action, efficacy and safety of denosumab and nivolumab (compared with nivolumab alone) in the neoadjuvant treatment of NSCLC will be assessed in POPCORN: Preoperative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC) (ACTRN12618001121257). This study was funded by an education grant provided by Amgen. Conduct of the study and all analysis will be performed by the investigators independent of Amgen.

Methods/design

Study aim

POPCORN is a signal-seeking study to provide information about the magnitude of pharmacodynamic effect, activity (clinical/pathological response) and safety of combination anti-RANKL (denosumab) and anti-PD1 (nivolumab) compared with anti-PD1 (nivolumab) alone in the preoperative treatment of
resectable NSCLC.

**Study population**

A total of 30 patients with NSCLC will be enrolled in this study. Eligible patients will be adults with stage IA (>2cm)-IIIA non-small cell lung cancer who have been deemed suitable for up-front curative treatment via surgery by a cardiothoracic surgeon as part of a lung cancer multidisciplinary team. Potential study participants will be identified through the lung cancer multidisciplinary teams at participating trial sites.

- **Inclusion and exclusion criteria**

Inclusion criteria were as follows: adult patients with histological or cytological diagnosis of NSCLC with 8th edition UICC/AJCC 2017 stage I, II or IIIA NSCLC (tumour ≥ 2 cm diameter) as assessed by staging investigations including by FDG-PET scan (with strong encouragement to pathologically confirm the status of suspected N2 nodes); measurable primary tumour on CT scan (3mm slice thickness) per RECIST criteria; sufficient baseline histological specimen from primary tumour (and locoregional lymph node metastasis if clinically suspected) available for translational research; no prior therapy for NSCLC; ECOG performance status 0-1; and adequate organ function. To be eligible for the study, patients must be considered to have potentially resectable disease on the basis of the preoperative investigations. They must be physiologically suitable for surgery, and the expected post-surgical FEV1 must be at least 1 L.

Exclusion criteria were as follows: patients with small cell or mixed small cell histology subtypes; prior malignancy within 5 years (other than non-melanoma skin cancer or adequately treated stage I in situ cervical cancer); recent receipt of another investigational drug or anti-cancer treatment; any prior treatment with therapies targeting T-cell immune checkpoint pathways or denosumab; active, known or suspected autoimmune disease (with certain exceptions such as vitiligo or type 1 diabetes mellitus); use of corticosteroids (at a dosage equivalent of 10 mg prednisolone per day or higher);
contraindication to corticosteroids; and concomitant medical or psychiatric disorders which would compromise the patient’s safety or participation (including dental disorders such as pre-existing osteonecrosis of the jaw, recent live vaccine, or serious hypersensitivity to trial drugs).

**Study design**

POPCORN is an open-label, multi-centre phase 1B/2 study with a pharmacodynamic endpoint. It will be conducted in 4 centres in Australia. Randomization by minimisation is performed at the Statistics Unit of Queensland Institute of Medical Research with stratification by histology (squamous vs. non-squamous) and tumour stage.

The schedule of study assessments is shown in Figure 1. CONSORT diagram for the trial is shown in Figure 2 (31). SPIRIT checklist is shown in Additional File 1.

A subject will have completed the study interventions approximately 8 weeks after the first dose of study drug (encompassing neoadjuvant treatment and surgery). All AEs will be followed up for a maximum of 90 days after the final dose of study drug; therefore the subject is considered as entering the survival follow-up phase after 90 days post-surgery. Subsequently, patients will be followed according to the institution’s standard practice. The close-out date of the trial will be three months after surgery for the final randomized participant, but with a further three years’ follow-up after the end of accrual to record long-term survival outcomes. Any adjuvant treatment, date and site of progression, date of death and cause of death will be recorded.

**Interventions**

Neoadjuvant systemic therapy will occur on two separate occasions, two weeks apart. In arm A, on each occasion participants will receive nivolumab (3 mg/kg i.v.) whereas in arm B, participants will receive nivolumab (3 mg/kg i.v.) and denosumab (120 mg s.c.) (Figure 3). All patients in arm B will also receive calcium and vitamin D supplementation unless hypercalcemia is present, and
hypocalcemia must be corrected prior to initiating therapy.

Surgery should be carried out on day 29 (± 3 days) of the study (2 weeks after the second dose of nivolumab +/- denosumab). The surgical operation to remove the primary tumour should be lobectomy, pneumonectomy or anatomical segmentectomy and other surgery as required. Thoracoscopic surgical techniques are permitted. Wedge resection or non-anatomical surgical dissection is not permitted. Surgery should also include appropriate mediastinal lymph node sampling or dissection and macroscopic margins of ≥ 2 cm and microscopic margins of ≥ 1 cm should be aimed for.

All patients should be offered appropriate adjuvant therapy as per institutional practice according to the recommendations of treating clinicians, preferably based on a multidisciplinary team review. It is strongly recommended this consist of 4 cycles of a platinum doublet chemotherapy (common regimen consisting of cisplatin 50 mg/m² days 1 and 8 and vinorelbine 25 mg/m² days 1, 8, 15 +/- 22 every 4 weeks for 4 cycles). Adjuvant chemotherapy should be considered in patients with pre-study nodal involvement (N1 or N2), a primary tumour >4cm and at the discretion of the treating investigator. Post-operative radiotherapy should also be considered in patients with pathologically confirmed N2 nodal involvement or positive surgical resection margins (R1 disease).

**Intervention safety monitoring and assessment**

Adverse events (AE), defined as any untoward medical occurrence(s) in a trial participant regardless of causality with trial interventions, will be systematically monitored and recorded. These will be classified and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 (NCI CTCAE v4.03). Serious AEs (SAE) will be reported to the appropriate ethics committees and competent authorities as well as the study safety committee. A suspected unexpected serious adverse reaction (SUSAR) which is an unexpected SAE related to the intervention will additionally be reported to the drug manufacturer. If the AE is deemed by the investigator to have
been caused, or probably caused, by the investigational treatment (nivolumab and/or denosumab), this will be labelled a TRAE (treatment-related adverse event).

Study participants will be reviewed clinically for the presence of AEs by the site investigator prior to each cycle of neoadjuvant therapy, prior to surgery, and four weeks following surgery. Blood tests, including complete blood count, liver and renal function tests, electrolytes, thyroid function tests and serum cortisol will be reviewed at these visits. Immune-related adverse events are managed following algorithms as compiled by expert groups or as available in the product information (32). Rechallenge after a suspected TRAE is permitted provided symptoms resolve to an appropriate level to meet criteria to resume treatment and do not meet any of the permanent discontinuation criteria (such as grade 4, and select grade 3 toxicities). Dose reductions and dose escalations are not permitted. An independent data safety monitoring committee will monitor the conduct and safety of the trial during recruitment.

A pregnancy test is mandated for women of childbearing age within 72 hours of commencing treatment and must be negative. Patients on study with reproductive potential, or female partners with reproductive potential, must use an effective contraceptive method during the trial and for 3 months after the completion of chemotherapy.

All patients are recommended to have a dental examination prior to commencing denosumab, maintain good oral hygiene while on denosumab, and avoid invasive dental procedures during treatment with denosumab and for at least a month after the final dose of denosumab. If osteonecrosis of the jaw is suspected, treatment with denosumab is halted and the patient assessed by a dentist or oral surgeon.

**Endpoints**

The primary endpoint is to define pharmacodynamic correlates of neoadjuvant therapy for each arm.
(combination anti-RANKL and anti-PD1 compared with anti-PD1 alone) in NSCLC. This is a signal-seeking study for this endpoint. Pharmacodynamic correlates will include the following parameters assessed in tumour and, where relevant, blood:

- T-cell receptor (TCR) clonality, comparing baseline and on-/post-treatment samples
- RNA/transcription profile changes for immune cells and other cells of interest, to define treatment response
- Analysis of genomic alterations, including estimation of expressed mutation-associated neoantigen load, and association with treatment response
- Expression of markers of interest via multiplex immunohistochemistry (formalin-fixed, paraffin-embedded tumour samples) and/or flow cytometry (fresh, dissociated tumour tissue or peripheral blood mononuclear cells)

Schedule for biobanking of clinical materials is shown in Figure 4. Formalin-fixed, paraffin-embedded tumour tissue will be stored at baseline (pre-treatment) and surgical timepoints, with participants strongly encouraged to consent for tumour biopsy for translational research purposes in the event of recurrent or metastatic disease. Collection of non-fixed tumour, including nodal metastases, will be performed where feasible with the assistance of trial site surgeon and pathologist. The fresh materials will be transported to the central laboratory (where possible within two hours of operation) and dissociated and processed on the same day. Blood will be collected at baseline, before each neoadjuvant systemic treatment, at the time of surgery, at the post-surgery visit, and in the event of tumour recurrence. This will be processed in the central trial laboratory, for storage of serum and peripheral blood mononuclear cells.

Secondary and exploratory endpoints are defined as follows, and will be compared between arms:

- The proportion of patients with evidence of pathological response as determined by blinded central pathology review, including major pathological response (MPR) (defined as <10% viable tumour cells in resected specimen)
- Response by CT scanning, with timepoint response assessed per RECIST v1.1 comparing baseline and pre-operative scans

Safety:

Rates of NCI CTCAE v4.03 grade 3-4 toxicity will be assessed by comparing the proportion of patients in each arm who are noted to have an AE of grade 3-4, regardless of causality. Proportion of patients in each arm who receive planned surgery without delay due to TRAE will be compared. If the surgery cannot proceed due to an unforeseen factor that was deemed by the investigator to probably not be caused by the investigational treatment, this will be recorded but will
not be deemed delay due to TRAE. A delay is defined as an event where the surgery is rescheduled for >24 hours later than originally planned due to clinical considerations. Feasibility of approach as reflected in R0 resection rate, which will be assessed based upon the operative and pathological report arising from the surgical resection. An R0 resection indicates that there is a microscopically- and macroscopically-negative margin. As an exploratory endpoint, progression-free survival (PFS) (defined as time between randomization and first evidence of disease progression or death from any cause) and overall survival (OS) (defined as time between randomization and death from any cause) will be recorded for trial participants in each group, for 3 years of follow-up or the latest available data, whichever is longer.

Statistical analysis

As a signal-seeking study, the emphasis of this project is on gaining an understanding of the mechanism of action, activity and safety of combination neoadjuvant therapy with denosumab and nivolumab. The sample size was based on estimated patient numbers available during the study period. The comparison of interest is between the combination neoadjuvant therapy compared to nivolumab alone. Categorical variables will be summarised as frequency and percentage and continuous variables as mean and standard deviation or median and interquartile range. A 95% confidence interval will be reported for primary outcomes. Categorical variables will be examined using the Pearson Chi-squared test or Fisher’s exact test when more than 20% of the expected value are less than 5. Continuous variables will be examined using the Student t-test or Mann-Whitney U test if data is not normally distributed. Paired data will be examined using a paired t-test or repeated measures ANOVA. Kaplan-Meier will be used to estimate progression-free survival and overall survival with the log-rank test used to assess differences between treatments. A Bonferroni correction will be used to adjust for the multiple primary endpoints.

The intention to treat population will be all patients with NSCLC randomized on the study. The as-treated population will be evaluable for toxicity and will include all patients who receive at least one dose of study therapy. After all 30 patients have completed the post-treatment assessment an interim toxicity analysis will be carried out. An interim analysis may also be undertaken for exploratory laboratory investigations on normal and tumour tissue.
Dissemination of results

The study results based on the trial data will be released to the participating physicians, referring physicians, patients and the general medical community. During study close-out, an interim period will be used to complete data collection, following which manuscript(s) based on trial results will be submitted to peer-reviewed journals. Authorship criteria as defined by the International Committee of Medical Journal Editors will be followed.

Discussion

Neoadjuvant trials provide a unique and valuable opportunity in translational research. As well as providing pharmacodynamic information about the mechanism of action of the neoadjuvant approach, other important questions can be explored such as biomarkers for response or resistance, and the expression of novel pathway markers and their modification over the time course of treatment. With respect to POPCORN, neoadjuvant immunotherapy in cancer has a sound preclinical rationale and other early-phase trials of neoadjuvant ICI with similar design are demonstrating impressive results in NSCLC. Given the well-characterised toxicity profile of denosumab, the investigators anticipate minimal additive AE with nivolumab; in particular, immune-related AEs are not associated with denosumab (22, 23). POPCORN is a small trial which is intended to assess the mechanism of action of a novel immunotherapy combination, and will allow an estimation of the magnitude of any incremental improvement in efficacy. If seen, this could help in the design of future, larger trials.

Trial Status

The first trial protocol and patient information and consent form was submitted for Human Research Ethics Committee on 30 July 2018 and amended documents (version 2.0) approved on 6 September 2018. It was last updated on 4th December 2018. The trial is open as of May 2019 and the first patient is expected to be consented in Q2, 2019.

Abbreviations

AE: adverse event

ECOG: Eastern Cooperative Oncology Group

ICI: immune checkpoint inhibitor

NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events
NSCLC: non-small cell lung cancer
PD1: programmed death-1
RANKL: receptor activator of NF-κB
RNA: ribonucleic acid
SAE: serious adverse event
SUSAR: suspected unexpected serious adverse reaction
TCR: T-cell receptor
TRAE: treatment-related adverse event
UICC/AJCC: Union for International Cancer Control/American Joint Committee on Cancer

Declarations

Acknowledgements

The authors thank the clinical trials unit of the Royal Brisbane and Women’s Hospital and all investigators.

Sponsor and funding source

POPCORN is sponsored by Metro North Hospital and Health Service (Queensland, Australia) and funded by an educational grant from Amgen, Inc. The funding body approved the trial proposal. Design of the trial and development of the protocol was performed by investigators independent of the funding body, as will also be the conduct of the study and all collection, analysis and interpretation of data. The funding body had/has no role in writing this or future manuscripts arising from the study.

Availability of data and materials

Not applicable as no datasets were analysed or generated during the creation of this manuscript.

Authors’ contributions

EA, MWLT, WCD, MJS and BGMH conceived the study. EA, AC, WCD, DG, RN and BGMH contributed to
the protocol development. EA, EB, WCD, AG and BGMH conceived and developed the statistical aspects of the study. EA drafted the manuscript. EA, AC, DG, RN and BGMH will run the study day-to-day. All authors reviewed approved the final version of the manuscript.

Ethics approval and consent to participate

The study (protocol, including qualitative and quantitative aspects, and trial materials including patient information and consent form) was reviewed and approved by the Human Research Ethics Committee of the Royal Brisbane and Women’s Hospital, Australia (reference number HREC/QRBW/43659) on 6th September 2018. This multisite approval covered all trial sites (comprising Royal Brisbane and Women’s Hospital, The Prince Charles Hospital, Princess Alexandra Hospital and Mater Adults Hospital). Informed consent will be obtained from all study participants.

Consent for publication

Not applicable.

Competing interests

ESA has received travel grants from Amgen and Bristol Myers Squibb. MJS has Scientific Research Agreements with Bristol Myers Squibb and Tizona Therapeutics and is on the Scientific Advisory Boards of Tizona Therapeutics and Compass Therapeutics. AG is an employee of Amgen. BGMH is an Advisory Board Member for Merck Sharp & Dohme, Bristol Myers Squibb, AstraZenica, Pfizer, Roche, Boehringer Ingelheim, and Eisai.

References

1. Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e278S-e313S.

2. Little AG, Rusch VW, Bonner JA, Gaspar LE, Green MR, Webb WR, et al. Patterns of
Surgical Care of Lung Cancer Patients. Ann Thorac Surg. 2005;80(6):2051-6.

3. Riaz SP, Linklater KM, Page R, Peake MD, Moller H, Luchtenborg M. Recent trends in resection rates among non-small cell lung cancer patients in England. Thorax. 2012;67(9):811-4.

4. Park S, Park IK, Kim ER, Hwang Y, Lee HJ, Kang CH, et al. Current Trends of Lung Cancer Surgery and Demographic and Social Factors Related to Changes in the Trends of Lung Cancer Surgery: An Analysis of the National Database from 2010 to 2014. Cancer Res Treat 2017;49(2):330-7.

5. Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review, 1975-2015, National Cancer Institute, Bethesda, MD, https://seer.cancer.gov/csr/1975_2015/. 2018.

6. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552-9.

7. Strauss GM, Herndon JE, 2nd, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008;26(31):5043-51.

8. Felip E, Rosell R, Maestre JA, Rodriguez-Paniagua JM, Moran T, Astudillo J, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol. 2010;28(19):3138-45.

9. Westeel V, Quoix E, Puyraveau M, Lavole A, Braun D, Laporte S, et al. A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-
cell lung cancer (IFCT 0002 trial). Eur J Cancer. 2013;49(12):2654-64.

10. Hellmann MD, Chaft JE, William WN, Jr., Rusch V, Pisters KMW, Kalhor N, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014;15(1):e42-e50.

11. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. New Eng J Med. 2015;373(17):1627-39.

12. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(2):123-35.

13. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255-65.

14. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540-50.

15. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csősz T, Fülöp A, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823-33.

16. Liu J, Blake SJ, Yong MCR, Harjunpää H, Ngio SF, Takeda K, et al. Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. Cancer Discov. 2016;6(12):1382-1399.
17. Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med. 2018;378(21):1976-86.

18. Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, et al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol. 2018;29(8):1853-60.

19. Rusch VW, Chaft JE, Johnson B, Wistuba II, Kris MG, Lee JM, et al. Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3). J Clin Oncol. 2018;36(15_suppl):8541.

20. Shu CA, Grigg C, Chiuzan C, Garofano RF, Patel V, Hernandez S, et al. Neoadjuvant atezolizumab + chemotherapy in resectable non-small cell lung cancer (NSCLC). J Clin Oncol. 2018;36(15_suppl):8532.

21. Provencio-Pulla M, Nadal-Alforja E, Cobo M, Insa A, Rivas MC, Majem M, et al. Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study—NADIM study-SLCG. J Clin Oncol. 2018;36(15_suppl):8521-.

22. Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, et al. Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012;11:401.

23. Ahern E, Smyth MJ, Dougall WC, Teng MWL. Roles of the RANKL-RANK axis in antitumour immunity - implications for therapy. Nat Rev Clin Oncol. 2018;15(11):676-93.

24. Ahern E, Harjunpaa H, O'Donnell JS, Allen S, Dougall WC, Teng MWL, et al. RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4
blockade in mouse models of cancer. Oncoimmunology. 2018;7(6):e1431088.

25. Ahern E, Harjunpaa H, Barkauskas D, Allen S, Takeda K, Yagita H, et al. Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice. Clin Cancer Res. 2017;23(19):5789-801.

26. Smyth MJ, Yagita H, McArthur GA. Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma. J Clin Oncol. 2016;34(12):e104-6.

27. Liede A, Hernandez RK, Wade SW, Bo R, Nussbaum NC, Ahern E, et al. An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer. Oncoimmunology. 2018;7(12):e1480301.

28. Rao S, Sigl V, Wimmer RA, Novatchkova M, Jais A, Wagner G, et al. RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer. Genes Dev. 2017;31(20):2099-112.

29. Scagliotti GV, Hirsh V, Siena S, Henry DH, Woll PJ, Manegold C, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol. 2012;7(12):1823-9.

30. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125-32.

31. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Br Med J. 2010;340:c332.

32. Roberts K, Culleton V, Lwin Z, O'Byrne K, Hughes BG. Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities. Asia-Pac J Clin Oncol. 2017;13(4):277-88.
### Study Period

| TIMEPOINT         | Enrolment | Allocation | Post-allocation | Close-out |
|-------------------|-----------|------------|-----------------|-----------|
| **≤18 days to**   | 0         | D1         | D15             | D29       |
| **D1**            |           |            | **surgery**     | **If re-** |
| **D15**           |           |            |                 | **lapse** |
| **D29**           |           |            |                 | **3 months** |
| **If re-lapse**   |           |            |                 | **final Pt** |

#### Enrollment:
- **Eligibility screen**: X
- **Informed consent**: X
- **Dental review recommendation**: X
- **Allocation**: X

#### Intervention:
- **Arm A: nivolumab plus ipilimumab**: X
- **Arm B: nivolumab**: X

#### Assessments:
- **Tumour histology, ECG**: X
- **Assessment of ECOG PS**: X
- **Physical exam and concomitant meds**: X
- **CT scan ± FDG-PET**: X
- **Bloods incl. CBC, U&E, LFT, TFT, cortisol**: X
| Event                                      | Tumour biopsy/collection | Blood for PBMC/serum storage | Record AEs | Record pathology (including MPR) and adjuvant Rx | Translational research; OS, PFS (3 years) |
|--------------------------------------------|--------------------------|-----------------------------|------------|--------------------------------------------------|----------------------------------------|
|                                            |                           |                             |            | X                                                | X                                      |
|                                            |                           | X                            | X          | X                                                | X                                      |
|                                            |                           | X                            | X          | X                                                | X                                      |

**Figure 1.** *Spirit* schedule of enrolment, interventions and assessments.

ECG electrocardiogram, ECOG PS Eastern Cooperative Oncology Group Performance Status, CT computed tomography, FDG-PET fluorodeoxyglucose-position emission tomography, CBC complete blood count, U&E urea and electrolytes, LFT liver function test, TFT thyroid function test, PBMC peripheral blood mononuclear cells, AE adverse events, MPR major pathological response, Rx treatment, OS overall survival, PFS progression-free survival.

---

Figure 1

*Spirit* schedule of enrolment, interventions and assessments. ECG electrocardiogram, ECOG PS Eastern Cooperative Oncology Group Performance Status, CT computed tomography, FDG-PET fluorodeoxyglucose-position emission tomography, CBC complete blood count, U&E urea and electrolytes, LFT liver function test, TFT thyroid function test, PBMC peripheral blood mononuclear cells, AE adverse events, MPR major pathological response, Rx treatment, OS overall survival, PFS progression-free survival.
Figure 2. CONSORT diagram of the POPCORN study.
Figure 3. POPCORN study schema. NSCLC non-small cell lung cancer, i.v. intravenous, s.c. subcutaneous.
Figure 4. Translational research schedule for collection of POPCORN trial biospecimens.

Figure acknowledgements: FFPE by Librepath - Own work, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=45097146; scalpel by Petit B - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=41650124.

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.

Additional File 1 Ahern et al Spirit checklist POPCORN 2019.pdf
POPCORN financial documentation.XLS
43659 signed approval letter.pdf